Abstract: on May 6, 2020, the United States food and drug administration (FDA) approved the karma for (Tabrecta Capmatinib) that is used to treat carry MET gene exon 14 jumping mutation of advanced NSCLC. On May 6, 2020, the United States food and dr...

On September 21, 2020, OncLive published a stage I CHRYSALIS research results, evaluate the Amivantamab, - 61186372) joint lazertinib (YH25448) in the initial and the west for late (Tagrisso) resistance of EGFR mutations in non-small cell lung cancer...